Diabetic Gastroparesis Candidate Fails in Phase 3

Evoke Pharma’s drug candidate EVK-001 sunk in a Phase 3 trial assessing its use in female patients with symptomatic diabetic gastroparesis.

The candidate failed to meet its primary endpoint of symptom improvement at week four, the California-based company said.

The company said that data from multiple clinical sites revealed patient improvement, but this was not consistent among all study locations.